

THE UNIVERSITY OF MICHIGAN  
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Project Agreements with the University of Michigan

Action Requested: Authorization to enter into or amend Agreements

Preamble:

Statutory conflicts of interest situations were identified by the Office of Research and Sponsored Projects while reviewing Proposal Approval Forms that then triggered a review by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. Plans for management of the possible risks associated with the conflicts of interest will be developed and approved by the Board and/or Committee and may require agreement by the parties involved at time of award.

These proposed project (e.g., research, sponsored activity, and/or subcontract) agreements (“Agreement”) and/or amendments to Agreements (“Amendments”) fall under the State of Michigan Conflict of Interest Statute because University of Michigan (“University”) employees have activities, relationships, or interests in the companies as described in Attachment A. The law permits such Agreements provided they are disclosed to the Board of Regents (“Regents”) of the University and approved in advance by a 2/3 vote.

Agreement Terms:

The terms of the Agreements and/or Amendments conform to University policy. The funding support will not exceed the amount reported in Attachment A for each Agreement and/or Amendment. Since projects are often amended, these Agreements and/or Amendments include provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreements and/or Amendments will provide support of investigator’s effort to use their expertise and University laboratories, as well as other University resources, to execute the projects as reported in Attachment A.

Recommendations:

These matters have been reviewed and approved by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreements and Amendments were negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into or amending the Agreements referenced in Attachment A.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Rebecca Cunningham', written in a cursive style.

Rebecca Cunningham  
Vice President for Research

March 2022

## Attachment A

### Project #1

SBIR Phase I Subcontract Agreement between the University and Amphionic, LLC Reviewed by the UMOR Conflict of Interest Review Committee	
<u>Project Information</u>	
<b>Title:</b> Non-hygroscopic Amorphous Organic Glass Scintillators Loaded with Transparent Lead for Dual Particle Detection and Imaging	<b>U-M Project ID:</b> 22-PAF05087
<b>Direct Sponsor:</b> Amphionic, LLC	<b>Prime Sponsor:</b> U.S. Department of Energy
<b>Principal Investigator/Department:</b> Mark Hammig, Nuclear Engineering & Radiological Sciences	
<b>Project Duration:</b> Eleven (11) Months	<b>Funding Support:</b> \$53,604
<b>Purpose:</b> The purpose of this project is to develop a non-hygroscopic amorphous glass scintillator for neutron/gamma dual particle sensing that possesses a high loading of transparent lead (Pb) nanoparticles.	
<b><u>University Employee; University Title; Relationship with Amphionic, LLC</u></b> <ul style="list-style-type: none"><li>• Mark Hammig; Professor, Nuclear Engineering &amp; Radiological Sciences; Partial Owner</li><li>• Suneel Joglekar; Research Fellow, Nuclear Engineering &amp; Radiological Sciences; CEO</li></ul>	

### Project #2

SBIR Phase I Subcontract Agreement between the University and Amphionic, LLC Reviewed by the UMOR Conflict of Interest Review Committee	
<u>Project Information</u>	
<b>Title:</b> Efficient, low-cost, high resolution imaging of hard x-rays using PbTe nanosemiconductor-based composites	<b>U-M Project ID:</b> 22-PAF05092
<b>Direct Sponsor:</b> Amphionic, LLC	<b>Prime Sponsor:</b> Defense Advanced Research Projects Agency
<b>Principal Investigator/Department:</b> Mark Hammig, Nuclear Engineering & Radiological Sciences	
<b>Project Duration:</b> Six (6) Months	<b>Funding Support:</b> \$67,341
<b>Purpose:</b> The purpose of this project is to develop an efficient, low-cost imager of hard x-rays (5 – 300 keV) that has high spatial (<55 $\mu\text{m}$ ) and energy resolutions (< 2 %).	
<b><u>University Employee; University Title; Relationship with Amphionic, LLC</u></b> <ul style="list-style-type: none"><li>• Mark Hammig; Professor, Nuclear Engineering &amp; Radiological Sciences; Partial Owner</li><li>• Suneel Joglekar; Research Fellow, Nuclear Engineering &amp; Radiological Sciences; CEO</li></ul>	

### Project #3

**SBIR Phase II Subcontract Agreement between the University and Arborsense, Inc.  
Reviewed by the UMOR Conflict of Interest Review Committee and the Medical School Conflict of Interest Board**

#### Project Information

<b>Title:</b> Rapid and non-invasive device for drug detection through sweat	<b>U-M Project ID:</b> 22-PAF03652
<b>Direct Sponsor:</b> Arborsense, Inc.	<b>Prime Sponsor:</b> National Institutes of Health
<b>Principal Investigator/Department:</b> Xudong Fan, Biomedical Engineering	
<b>Project Duration:</b> Two (2) Years	<b>Funding Support:</b> \$475,284
<b>Purpose:</b> The purpose of this project is to design, co-develop, and validate a portable sweat-based detector in a large-scale human study.	

#### University Employee; University Title; Relationship with Arborsense, Inc.

- Xudong Fan; Professor, Biomedical Engineering; Partial Owner
- Zhaohui Zhong; Associate Professor, Electrical Engineering and Computer Science – Electrical and Computer Engineering Division; Partial Owner
- Mark Ilgen; Professor, Psychiatry; Partial Owner

### Project #4

**Research Agreement between the University and Ascentage Pharma Group Corporation, Ltd.  
Reviewed by the Medical School Conflict of Interest Board**

#### Project Information

<b>Title:</b> A Phase Ib/II Open-Label Study of APG2575 in Combination with Novel Therapeutic Regimens in Subjects with Relapsed or Refractory Multiple Myeloma and Immunoglobulin light Chain Amyloidosis	<b>U-M Project ID:</b> 22-PAF02911
<b>Direct Sponsor:</b> Ascentage Pharma Group Corporation, Ltd.	
<b>Principal Investigator/Department:</b> Jing Christine Ye, Internal Medicine – Hematology/Oncology	
<b>Project Duration:</b> Four (4) Years	<b>Funding Support:</b> \$1,653,641
<b>Purpose:</b> The purpose of this project is to evaluate the safety and tolerability, identify dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD / recommended phase II dose (RP2D) of APG2575 in combination with Pomalidomide/dexamethasone (Pd) in patients with relapsed/refractory (R/R) multiple myeloma (MM) or immunoglobulin light chain (AL) amyloidosis.	

#### University Employee; University Title; Relationship with Ascentage Pharma Group Corporation, Ltd.

- Shaomeng Wang; Professor, Internal Medicine – Hematology/Oncology; Partial Owner

### Project #5

#### STTR Phase II Subcontract Agreement between the University and Courage Therapeutics, Inc. Reviewed by the UMOR Conflict of Interest Review Committee

##### Project Information

**Title:** Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment of MC4R Haploinsufficiency

**U-M Project ID:** 22-PAF03865

**Direct Sponsor:** Courage Therapeutics, Inc.

**Prime Sponsor:** National Institutes of Health

**Principal Investigator/Department:** Roger Cone, Life Sciences Institute

**Project Duration:** Two (2) Years

**Funding Support:** \$775,536

**Purpose:** The purpose of this project is to understand the physiological functions of the melanocortin-3 receptor (MC3R) antagonist peptide.

##### University Employee; University Title; Relationship with Courage Therapeutics, Inc.

- Roger Cone; Vice Provost and Director of the Biosciences Initiative, Executive Vice President for Academic Affairs, and Director of the Life Sciences Institute; Partial Owner

### Project #6

#### Other Sponsored Activity Agreement between the University and Eli Lilly and Company Reviewed by the Medical School Conflict of Interest Board

##### Project Information

**Title:** Eli Lilly Consulting agreement 2022

**U-M Project ID:** 22-PAF04718

**Direct Sponsor:** Eli Lilly and Company

**Principal Investigator/Department:** Ronald Chervin, Neurology Department

**Project Duration:** Two (2) Years

**Funding Support:** \$45,000

**Purpose:** The purpose of this project is to provide consultation services for tirzepatide (LY3298176) study I8F-MC-GPIF, including clinical research strategy consultation, participation on steering committee, and study design consultation.

##### University Employee; University Title; Relationship with Eli Lilly and Company

- Marschall Runge; Executive Vice President for Medical Affairs and Dean of the Medical School; Board of Directors Member

### Project #7

**Amendment to an Other Sponsored Activity Agreement between the University and EVOQ Therapeutics LLC**  
**Reviewed by the UMOR Conflict of Interest Review Committee**

#### Project Information

**Title:** EVOQ General Service Agreement 3 - Amend1

**U-M Project ID:** 22-PAF05083

**Direct Sponsor:** EVOQ Therapeutics LLC

**Principal Investigator/Department:** James Moon, Pharmaceutical Sciences

**Agreement Initiated:** March 2, 2021

**Current Project Duration:** Two (2) Years  
**Additional Time:** N/A

**Current Funding Support:** \$400,000  
**Additional Funding Support:** \$200,000

**Purpose:** The purpose of this amendment is to add additional funds for two additional categories of nanodisk work to be added to the services agreement.

#### University Employee; University Title; Relationship with EVOQ Therapeutics LLC

- James Moon; Professor, Pharmaceutical Sciences; Partial Owner
- Anna Schwendeman; Professor, Pharmaceutical Sciences; Partial Owner

### Project #8

**STTR Phase II Subcontract Agreement between the University and iReprogram, LLC**  
**Reviewed by the Medical School Conflict of Interest Board**

#### Project Information

**Title:** Autologous Hematopoietic Stem Cell Production to End Graft-Versus-Host Disease

**U-M Project ID:** 22-PAF04478

**Direct Sponsor:** iReprogram, LLC

**Prime Sponsor:** National Science Foundation

**Principal Investigator/Department:** Indika Rajapakse, Computational Medicine & Bioinformatics

**Project Duration:** One (1) Year

**Funding Support:** \$308,283

**Purpose:** The purpose of this project is to test sets of transcription factors predicted to generate hematopoietic stem cells (HSCs). These transcription factor regimens will be applied to several starting cell phenotypes under several growth conditions. The resulting HSC-like cells will be compared to primary human HSCs, tested in niche microenvironments, and analyzed by Hi-C, RNA-seq, and imaging.

#### University Employee; University Title; Relationship with iReprogram, LLC

- Indika Rajapakse; Associate Professor, Computational Medicine & Bioinformatics; Partial Owner
- Lindsey Muir; Research Assistant Professor, Computational Medicine & Bioinformatics; Partial Owner
- Walter Meixner; Research Laboratory Specialist Senior, Computational Medicine & Bioinformatics; Partial Owner

### Project #9

#### Phase IV Subcontract Agreement between the University and Jacobs Engineering Group Inc. Reviewed by the UMOR Conflict of Interest Review Committee

##### Project Information

**Title:** Ecotoxicological Study of Waters Adjacent to South Pond (Ludington, MI)

**U-M Project ID:** 22-PAF05069

**Direct Sponsor:** Jacobs Engineering Group Inc.

**Prime Sponsor:** The Dow Chemical Company

**Principal Investigator/Department:** Allen Burton, School for Environment and Sustainability

**Project Duration:** Nine (9) Months

**Funding Support:** \$88,187

**Purpose:** The purpose of this project is to evaluate and determine the potential effects of dissolved oxygen and ammonia on benthic communities in areas adjacent to South Pond.

**University Employee; University Title; Relationship with Jacobs Engineering Group Inc.**

- Glen Daigger; Professor, Civil and Environmental Engineering; Partial Owner

### Project #10

#### Amendment to an STTR Phase I Subcontract Agreement between the University and PhotoSonoX LLC Reviewed by the Medical School Conflict of Interest Board

##### Project Information

**Title:** Novel Nanosecond Laser and Ultrasound to Selectively Treat Eye Neovascularization

**U-M Project ID:** 22-PAF04845

**Direct Sponsor:** PhotoSonoX LLC

**Prime Sponsor:** National Institutes of Health

**Principal Investigator/Department:** Yannis Paulus, Ophthalmology & Visual Science

**Agreement Initiated:** June 1, 2020

**Current Project Duration:** One (1) Year  
**Additional Time:** One (1) Year

**Current Funding Support:** \$75,127  
**Additional Funding Support:** \$55,873

**Purpose:** The purpose of this amendment is to add additional funds and time in support Dr. Paulus' continued efforts related to wet age-related macular degeneration (AMD) where choroidal neovascularization (CNV) is the primary cause of vision loss.

**University Employee; University Title; Relationship with PhotoSonoX LLC**

- Yannis Paulus; Assistant Professor, Ophthalmology & Visual Science; Partial Owner
- Xueding Wang; Professor, Radiology; Partial Owner